O	0	9	Defective
B-Glycosylation	10	23	glycosylation
O	24	26	of
B-Protein	27	34	decorin
O	35	38	and
B-Protein	39	47	biglycan
O	47	48	,
O	49	56	altered
O	57	65	collagen
O	66	75	structure
O	75	76	,
O	77	80	and
O	81	89	abnormal
O	90	99	phenotype
O	100	102	of
O	103	106	the
O	107	111	skin
O	112	123	fibroblasts
O	124	126	of
O	127	129	an
O	130	136	Ehlers
O	136	137	-
O	137	143	Danlos
O	144	152	syndrome
O	153	160	patient
O	161	169	carrying
O	170	173	the
O	174	179	novel
O	180	189	Arg270Cys
O	190	202	substitution
O	203	205	in
O	206	227	galactosyltransferase
O	228	229	I
O	230	231	(
B-Protein	231	240	beta4GalT
I-Protein	240	241	-
I-Protein	241	242	7
O	242	243	)
O	243	244	.

O	246	249	The
O	250	256	Ehlers
O	256	257	-
O	257	263	Danlos
O	264	272	syndrome
O	273	274	(
O	274	277	EDS
O	277	278	)
O	279	281	is
O	282	283	a
O	284	297	heterogeneous
O	298	303	group
O	304	306	of
O	307	317	connective
O	318	324	tissue
O	325	334	disorders
O	335	344	affecting
O	345	349	skin
O	350	353	and
O	354	359	joint
O	360	368	function
O	368	369	.

O	370	379	Molecular
O	380	387	defects
O	388	390	in
O	391	404	extracellular
O	405	411	matrix
O	412	420	proteins
O	420	421	,
O	422	431	including
O	432	440	collagen
O	441	442	(
O	442	446	type
O	447	448	I
O	448	449	,
O	450	453	III
O	453	454	,
O	455	458	and
O	459	460	V
O	460	461	)
O	462	465	and
B-Protein	466	474	tenascin
I-Protein	475	476	X
O	477	480	are
O	481	491	associated
O	492	496	with
O	497	506	different
O	507	512	forms
O	513	515	of
O	516	519	EDS
O	519	520	.

O	521	529	Compound
O	530	542	heterozygous
O	543	552	mutations
O	553	555	in
O	556	559	the
B-Protein	560	567	B4GALT7
O	568	572	gene
O	572	573	,
O	574	583	resulting
O	584	586	in
O	587	595	aberrant
B-Glycosylation	596	609	glycosylation
O	610	612	of
O	613	616	the
B-Entity	617	625	dermatan
I-Entity	626	633	sulfate
O	634	646	proteoglycan
B-Protein	647	654	decorin
O	654	655	,
O	656	659	had
O	660	664	been
O	665	674	described
O	675	677	in
O	678	679	a
O	680	686	single
O	687	694	patient
O	695	703	affected
O	704	708	with
O	709	712	the
O	713	722	progeroid
O	723	727	form
O	728	730	of
O	731	734	EDS
O	734	735	.

O	736	738	We
O	739	743	have
O	744	751	studied
O	752	755	the
O	756	765	molecular
O	766	775	phenotype
O	776	778	of
B-Protein	779	786	decorin
O	786	787	,
B-Protein	788	796	biglycan
O	796	797	,
O	798	801	and
O	802	810	collagen
O	811	815	type
O	816	817	I
O	818	828	containing
O	829	836	fibrils
O	837	839	in
O	840	844	skin
O	845	856	fibroblasts
O	857	859	of
O	860	861	a
O	862	869	patient
O	870	878	carrying
O	879	882	the
O	883	888	novel
O	889	899	homozygous
O	900	905	C808T
O	906	911	point
O	912	920	mutation
O	921	923	in
O	924	927	the
B-Protein	928	935	B4GALT7
O	936	940	gene
O	940	941	,
O	942	947	which
O	948	954	causes
O	955	957	an
O	958	967	Arg270Cys
O	968	980	substitution
O	981	983	in
B-Protein	984	993	beta4GalT
I-Protein	993	994	-
I-Protein	994	995	7
O	995	996	.

O	997	1005	Compared
O	1006	1008	to
O	1009	1016	control
O	1017	1028	fibroblasts
O	1028	1029	,
O	1030	1051	galactosyltransferase
O	1052	1060	activity
O	1061	1063	in
B-Protein	1064	1073	beta4GalT
I-Protein	1073	1074	-
I-Protein	1074	1075	7
O	1075	1076	(
O	1076	1085	Arg270Cys
O	1085	1086	)
O	1087	1092	cells
O	1093	1096	was
O	1097	1110	approximately
O	1111	1116	three
O	1117	1122	times
O	1123	1130	reduced
O	1131	1135	over
O	1136	1137	a
O	1138	1149	temperature
O	1150	1155	range
O	1156	1158	of
O	1159	1161	25
O	1161	1162	-
O	1162	1164	41
O	1165	1172	degrees
O	1173	1174	C
O	1174	1175	.

O	1176	1181	Pulse
O	1181	1182	-
O	1182	1187	chase
O	1188	1199	experiments
O	1200	1203	and
O	1204	1212	confocal
O	1213	1223	microscopy
O	1224	1236	demonstrated
O	1237	1241	that
O	1242	1251	synthesis
O	1252	1255	and
O	1256	1265	secretion
O	1266	1268	of
B-Protein	1269	1276	decorin
O	1277	1281	were
O	1282	1288	normal
O	1289	1291	in
B-Protein	1292	1301	beta4GalT
I-Protein	1301	1302	-
I-Protein	1302	1303	7
O	1303	1304	(
O	1304	1313	Arg270Cys
O	1313	1314	)
O	1315	1320	cells
O	1320	1321	.

O	1322	1329	However
O	1329	1330	,
O	1331	1336	about
O	1337	1339	50
O	1339	1340	%
O	1341	1343	of
B-Protein	1344	1351	decorin
O	1352	1356	were
O	1357	1368	synthesized
O	1369	1371	as
O	1372	1373	a
O	1374	1381	protein
O	1382	1386	core
O	1387	1389	in
O	1390	1398	addition
O	1399	1401	to
O	1402	1405	its
O	1406	1418	proteoglycan
O	1419	1423	form
O	1423	1424	.

B-Protein	1425	1433	Biglycan
O	1434	1437	was
O	1438	1443	found
O	1444	1446	in
O	1447	1448	a
B-Glycosylation	1449	1463	monoglycanated
O	1464	1468	form
O	1469	1471	in
O	1472	1480	addition
O	1481	1483	to
O	1484	1487	its
O	1488	1494	mature
O	1495	1499	form
O	1499	1500	.

O	1501	1518	Glycosaminoglycan
O	1519	1525	chains
O	1526	1530	were
O	1531	1533	of
O	1534	1537	the
O	1538	1546	dermatan
O	1546	1547	/
O	1547	1558	chondroitin
O	1559	1566	sulfate
O	1567	1571	type
O	1572	1576	both
O	1577	1579	in
B-Protein	1580	1589	beta4GalT
I-Protein	1589	1590	-
I-Protein	1590	1591	7
O	1591	1592	(
O	1592	1601	Arg270Cys
O	1601	1602	)
O	1603	1606	and
O	1607	1614	control
O	1615	1620	cells
O	1620	1621	,
O	1622	1625	and
O	1626	1639	epimerization
O	1640	1643	was
O	1644	1651	reduced
O	1652	1655	for
B-Protein	1656	1663	decorin
O	1664	1667	and
B-Protein	1668	1676	biglycan
O	1676	1677	.

O	1678	1686	Compared
O	1687	1689	to
O	1690	1697	control
O	1698	1703	cells
O	1703	1704	,
B-Protein	1705	1714	beta4GalT
I-Protein	1714	1715	-
I-Protein	1715	1716	7
O	1716	1717	(
O	1717	1726	Arg270Cys
O	1726	1727	)
O	1728	1733	cells
O	1734	1740	showed
O	1741	1748	altered
O	1748	1749	,
O	1750	1756	highly
O	1757	1763	spread
O	1764	1766	or
O	1767	1776	stretched
O	1777	1787	phenotypes
O	1788	1791	and
O	1792	1801	decreased
O	1802	1815	proliferation
O	1816	1821	rates
O	1821	1822	.

O	1823	1825	At
O	1826	1829	the
O	1830	1845	ultrastructural
O	1846	1851	level
O	1851	1852	,
O	1853	1855	an
O	1856	1869	intracellular
O	1870	1882	accumulation
O	1883	1885	of
O	1886	1894	multiple
O	1895	1904	secondary
O	1905	1914	lysosomes
O	1915	1918	and
O	1919	1931	degenerative
O	1932	1940	vacuoles
O	1941	1944	was
O	1945	1949	seen
O	1950	1952	in
B-Protein	1953	1962	beta4GalT
I-Protein	1962	1963	-
I-Protein	1963	1964	7
O	1964	1965	(
O	1965	1974	Arg270Cys
O	1974	1975	)
O	1976	1981	cells
O	1981	1982	.

O	1983	1994	Furthermore
O	1994	1995	,
O	1996	1999	the
O	2000	2008	collagen
O	2009	2024	suprastructures
O	2025	2029	were
O	2030	2037	altered
O	2038	2040	in
O	2041	2044	the
B-Protein	2045	2054	beta4GalT
I-Protein	2054	2055	-
I-Protein	2055	2056	7
O	2056	2057	(
O	2057	2066	Arg270Cys
O	2066	2067	)
O	2068	2073	cells
O	2073	2074	.

O	2075	2078	The
O	2079	2086	reduced
B-Protein	2087	2096	beta4GalT
I-Protein	2096	2097	-
I-Protein	2097	2098	7
O	2099	2107	activity
O	2108	2117	resulting
O	2118	2120	in
O	2121	2130	defective
B-Glycosylation	2131	2144	glycosylation
O	2145	2147	of
B-Protein	2148	2155	decorin
O	2156	2159	and
B-Protein	2160	2168	biglycan
O	2169	2172	may
O	2173	2175	be
O	2176	2187	responsible
O	2188	2191	for
O	2192	2195	the
O	2196	2203	complex
O	2204	2213	molecular
O	2214	2223	pathology
O	2224	2226	in
B-Protein	2227	2236	beta4GalT
I-Protein	2236	2237	-
I-Protein	2237	2238	7
O	2239	2248	deficient
O	2249	2252	EDS
O	2253	2261	patients
O	2261	2262	,
O	2263	2268	given
O	2269	2272	the
O	2273	2277	role
O	2278	2280	of
O	2281	2286	these
O	2287	2300	proteoglycans
O	2301	2303	in
O	2304	2308	bone
O	2309	2318	formation
O	2318	2319	,
O	2320	2328	collagen
O	2329	2344	fibrillogenesis
O	2344	2345	,
O	2346	2349	and
O	2350	2358	skeletal
O	2359	2365	muscle
O	2366	2377	development
O	2377	2378	.
